A new trading day began on Friday, with Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) stock price up 3.33% from the previous day of trading, before settling in for the closing price of $0.50. LXRX’s price has ranged from $0.28 to $2.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 600.60% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 41.27%. With a float of $179.54 million, this company’s outstanding shares have now reached $361.49 million.
In an organization with 103 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.55%, operating margin of -634.2%, and the pretax margin is -644.78%.
Lexicon Pharmaceuticals Inc (LXRX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lexicon Pharmaceuticals Inc is 50.33%, while institutional ownership is 34.83%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000.
Lexicon Pharmaceuticals Inc (LXRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.27% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Here are Lexicon Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 10.65 million. That was inferior than the volume of 14.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 47.70%. Additionally, its Average True Range was 0.09.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 28.62%, which indicates a significant decrease from 49.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 256.31% in the past 14 days, which was higher than the 195.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5320, while its 200-day Moving Average is $1.1945. However, in the short run, Lexicon Pharmaceuticals Inc’s stock first resistance to watch stands at $0.5279. Second resistance stands at $0.5439. The third major resistance level sits at $0.5729. If the price goes on to break the first support level at $0.4829, it is likely to go to the next support level at $0.4539. The third support level lies at $0.4379 if the price breaches the second support level.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
With a market capitalization of 185.01 million, the company has a total of 246,237K Shares Outstanding. Currently, annual sales are 31,080 K while annual income is -200,400 K. The company’s previous quarter sales were 26,550 K while its latest quarter income was -33,770 K.
